US › Healthcare

MetaVia Inc. (MTVA)

US · Healthcare · Biotechnology

$1.59+3.25%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.3M

EPS

$-0.90

EPS estimate

$-0.85

EPS came in at -0.90 against a street estimate of -0.85 — a miss of 5.9%.

Key statistics

Market cap

$10.9M

Forward P/E

0.0

P/B

1.60

Book value

$1.04

EPS (TTM)

$-2.45

52-week high

$19.03

52-week low

$0.97

50-day MA

$1.60

200-day MA

$2.90

Beta

0.94

Analyst view

Analysts rate MetaVia Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $19.33.

Shareholding

Insiders

28.61%

Institutions

13.87%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	0.93%
Geode Capital Management, LLC	0.51%
Jane Street Group LLC	0.17%
Aries Wealth Management	0.15%
Vanguard Fiduciary Trust Co	0.11%
Tower Research Capital LLC	0.04%
Vanguard Capital Management, LLC	0.03%
BlackRock Inc	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MetaVia Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.